NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Positive results from AELIX’ HIV therapeutic vaccine clinical study published in Nature Medicine<
02 Nov 2022

Positive results from AELIX’ HIV therapeutic vaccine clinical study published in Nature Medicine

The study achieved its primary and secondary endpoints of safety, tolerability and immunogenicity.
AM-Pharma provides business update and outcome of pre-planned interim futility analysis of phase 3 REVIVAL study<
20 Oct 2022

AM-Pharma provides business update and outcome of pre-planned interim futility analysis of phase 3 REVIVAL study

Clear path forward for ilofotase alfa as potential treatment in acute kidney injury.
Xeltis presented promising FIH data on restorative hemodialysis access graft at PVC congress<
17 Oct 2022

Xeltis presented promising FIH data on restorative hemodialysis access graft at PVC congress

Enrollment in Xeltis’ AXESS multi-center clinical trial now successfully completed
SparingVision Presents Validating Data of its Lead Gene Therapy Programs, SPVN06 and SPVN20, at ESGCT 2022<
13 Oct 2022

SparingVision Presents Validating Data of its Lead Gene Therapy Programs, SPVN06 and SPVN20, at ESGCT 2022

Data supports progression into first-in-human clinical trial with SPVN06
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022<
03 Oct 2022

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022

Aura to Host Virtual Investor Day at 11:30 a.m. Eastern Time
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target<
29 Sep 2022

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target

Announced positive results from a planned intermediate assessment of its ongoing Phase 2a trial of GB2064 for the treatment of myelofibrosis
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer<
29 Sep 2022

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

The Phase 1 multi-center, open label clinical trial is expected to enroll approximately 23 adult patients with NMIBC.
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors<
27 Sep 2022

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

LAVA to Receive Upfront Payment of $50 Million, With Potential for Milestones of up to Approximately $650 Million and Royalties
Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD)<
14 Sep 2022

Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD)

The EMA has now validated the MAA file and it is under review by the Committee for Medicinal Products for Human Use (CHMP).
SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases<
14 Sep 2022

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases

Proceeds to fund first-in-human trials of breakthrough gene therapy products and advance CRISPR-based genome editing portfolio.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.